BeOne Medicines Receives US FDA Accelerated Approval for Beqalzi (Sonrotoclax) to Treat R/R Mantle Cell Lymphoma

Why It Matters

Beqalzi becomes the first BCL‑2‑targeted therapy for relapsed/refractory mantle‑cell lymphoma, expanding options for a high‑unmet‑need population and unlocking a new revenue stream for BeOne while shaping future combination strategies.

Key Takeaways

• Beqalzi earned FDA accelerated approval for relapsed/refractory mantle cell lymphoma.
• Phase I/II trial showed 52% overall response, 16% complete responses.
• Median time to response was 1.9 months; duration 15.8 months.
• Approval hinges on Phase III CELESTIAL trial confirming clinical benefit.
• Combination studies with Brukinsa aim to expand indications by 2026.

Pulse Analysis

Mantle‑cell lymphoma (MCL) remains one of the most aggressive non‑Hodgkin lymphomas, with patients often exhausting standard chemo‑immunotherapy, BTK inhibitors, and stem‑cell transplant. The disease’s reliance on the BCL‑2 survival pathway has made it an attractive target, yet no BCL‑2 inhibitor has previously cleared the U.S. regulatory hurdle for this indication. Beqalzi’s entry therefore addresses a clear therapeutic gap, offering a novel mechanism that can induce rapid tumor regression in a population with limited options.

The FDA’s accelerated approval was anchored in robust Phase I/II data: a 52% overall response rate, including 16% complete remissions, and a median time to response of just 1.9 months. These metrics compare favorably with existing salvage regimens, which typically yield lower response rates and longer timeframes to effect. By leveraging the accelerated pathway, the agency signaled confidence in the drug’s potential while mandating a confirmatory Phase III trial (CELESTIAL‑RRMCL) to verify long‑term benefit, a standard safeguard for oncology approvals.

Looking ahead, BeOne is positioning Beqalzi as a platform for combination therapies, notably with Brukinsa (zanubrutinib) in chronic lymphocytic leukemia, and expects pivotal data at ASCO 2026. Successful combos could broaden the drug’s label beyond MCL, driving cross‑indication sales and strengthening its competitive stance against other BCL‑2 agents like venetoclax. Simultaneously, an ongoing EU review could unlock additional market access, further amplifying the commercial upside for BeOne’s pipeline.